title: [Recommendation for the optimal use of bendamustine in Japan].
authors.forename: Ken
authors.initials: K
authors.lastname: Ohmachi
authors.forename: Dai
authors.initials: D
authors.lastname: Maruyama
authors.forename: Momoko
authors.initials: M
authors.lastname: Nisikori
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Suzuki
authors.forename: Koji
authors.initials: K
authors.lastname: Izutsu
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000150:complications; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D019317:Evidence-Based Medicine; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D007564:Japan; D016393:Lymphoma, B-Cell / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D020522:Lymphoma, Mantle-Cell / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D009894:Opportunistic Infections / Q000150:complications; D000069283:Rituximab; D014657:Vasculitis / Q000209:etiology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride